Daily Pill Boosts Growth in Children with Most Common Dwarfism Disorder
A once-daily oral drug significantly increased height velocity in children with achondroplasia, offering an alternative to daily injections.
Summary
Achondroplasia, the most common form of dwarfism, is caused by a genetic mutation that overactivates FGFR3, stunting bone growth. A phase III trial called PROPEL 3 tested infigratinib, a once-daily oral pill that directly blocks FGFR3 signaling. Children taking infigratinib gained 1.74 cm/year more in height velocity compared to placebo over 52 weeks. Unlike existing injectable therapies, this drug targets multiple downstream signaling pathways simultaneously. The effect was strongest in younger children aged 3 to 7 and those who had not yet entered puberty. Published in the New England Journal of Medicine, these results position infigratinib as a promising oral alternative to current injectable treatments for achondroplasia.
Detailed Summary
Achondroplasia affects roughly 1 in 25,000 births and is the most common genetic cause of short stature. It results from gain-of-function mutations in the FGFR3 gene, which overactivates pathways that suppress bone growth. Until now, approved treatments required daily injections, creating adherence challenges particularly in young children.
The phase III PROPEL 3 trial, published in the New England Journal of Medicine, tested infigratinib — an oral tyrosine kinase inhibitor targeting FGFR1-3 — in children with achondroplasia across 27 sites in 10 countries. At 52 weeks, children on infigratinib showed a mean annualized height velocity increase of 1.58 cm/year versus a decline of 0.16 cm/year in the placebo group, a statistically significant difference of 1.74 cm/year. The achondroplasia-specific height z-score also improved meaningfully.
A key mechanistic distinction sets infigratinib apart from the two currently approved therapies — vosoritide and navepegritide, both C-type natriuretic peptide analogues. Those drugs reduce FGFR3 signaling only through the MAPK pathway, while infigratinib directly binds and inhibits FGFR3 phosphorylation, blocking all downstream signaling pathways involved in impaired bone growth, including both MAPK and STAT1. Researchers suggest this broader inhibition may offer a therapeutic advantage.
The growth benefit was most pronounced in children aged 3 to 7 years and in pre-pubertal children at Tanner stage 1, suggesting earlier treatment initiation may yield the greatest benefit. The effect on body proportions trended positive but did not reach statistical significance.
The oral delivery format is clinically significant: eliminating daily injections could substantially improve adherence and quality of life for affected children and families. Infigratinib's efficacy was comparable to existing injectables while offering a more convenient administration route. Longer-term data on safety, final adult height, and body proportion outcomes are still needed before full clinical adoption.
Key Findings
- Infigratinib increased annualized height velocity by 1.74 cm/year over placebo in children with achondroplasia at 52 weeks.
- The drug directly inhibits FGFR3 phosphorylation, blocking more downstream growth-suppressing pathways than current injectable options.
- Height gains were most pronounced in children aged 3 to 7 years and pre-pubertal children at Tanner stage 1.
- Once-daily oral dosing offers a meaningful adherence advantage over existing daily injectable therapies.
- Results were published in the New England Journal of Medicine, representing high-quality phase III evidence.
Methodology
This is a news report summarizing a phase III randomized, double-blind, placebo-controlled trial published in the New England Journal of Medicine. The source, MedPage Today, is a credible medical news outlet. The evidence basis is strong: a multicenter trial across 27 sites in 10 countries with objective height velocity measurements at 52 weeks.
Study Limitations
The article does not provide complete safety data, total sample size after screening, or information on long-term outcomes such as final adult height or skeletal proportions. The 52-week trial window limits conclusions about sustained efficacy. Independent replication and regulatory review are pending before clinical availability.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: